AU2018328827B2 - Methods and compositions for treating chronic lung diseases - Google Patents

Methods and compositions for treating chronic lung diseases Download PDF

Info

Publication number
AU2018328827B2
AU2018328827B2 AU2018328827A AU2018328827A AU2018328827B2 AU 2018328827 B2 AU2018328827 B2 AU 2018328827B2 AU 2018328827 A AU2018328827 A AU 2018328827A AU 2018328827 A AU2018328827 A AU 2018328827A AU 2018328827 B2 AU2018328827 B2 AU 2018328827B2
Authority
AU
Australia
Prior art keywords
weeks
months
igf
pma
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018328827A
Other languages
English (en)
Other versions
AU2018328827A1 (en
Inventor
Norman Barton
Alexandra MANGILI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oak Hill Bio Ltd
Original Assignee
Oak Hill Bio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oak Hill Bio Ltd filed Critical Oak Hill Bio Ltd
Publication of AU2018328827A1 publication Critical patent/AU2018328827A1/en
Assigned to TAKEDA PHARMACEUTICAL COMPANY LIMITED reassignment TAKEDA PHARMACEUTICAL COMPANY LIMITED Request for Assignment Assignors: SHIRE HUMAN GENETIC THERAPIES, INC.
Assigned to OAK HILL BIO LIMITED reassignment OAK HILL BIO LIMITED Request for Assignment Assignors: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Application granted granted Critical
Publication of AU2018328827B2 publication Critical patent/AU2018328827B2/en
Priority to AU2024227601A priority Critical patent/AU2024227601B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1754—Insulin-like growth factor binding proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AU2018328827A 2017-09-11 2018-09-11 Methods and compositions for treating chronic lung diseases Active AU2018328827B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024227601A AU2024227601B2 (en) 2017-09-11 2024-10-24 Methods and compositions for treating chronic lung diseases

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762557113P 2017-09-11 2017-09-11
US62/557,113 2017-09-11
PCT/US2018/050427 WO2019051474A1 (en) 2017-09-11 2018-09-11 METHODS AND COMPOSITIONS FOR TREATING CHRONIC PULMONARY DISEASES

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024227601A Division AU2024227601B2 (en) 2017-09-11 2024-10-24 Methods and compositions for treating chronic lung diseases

Publications (2)

Publication Number Publication Date
AU2018328827A1 AU2018328827A1 (en) 2020-04-02
AU2018328827B2 true AU2018328827B2 (en) 2024-07-25

Family

ID=63794620

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018328827A Active AU2018328827B2 (en) 2017-09-11 2018-09-11 Methods and compositions for treating chronic lung diseases
AU2024227601A Active AU2024227601B2 (en) 2017-09-11 2024-10-24 Methods and compositions for treating chronic lung diseases

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2024227601A Active AU2024227601B2 (en) 2017-09-11 2024-10-24 Methods and compositions for treating chronic lung diseases

Country Status (21)

Country Link
US (3) US20190151411A1 (enExample)
EP (2) EP4663184A3 (enExample)
JP (3) JP7819893B2 (enExample)
KR (1) KR20200097679A (enExample)
CN (1) CN111432881A (enExample)
AU (2) AU2018328827B2 (enExample)
BR (1) BR112020004760A2 (enExample)
CA (1) CA3075482A1 (enExample)
CL (1) CL2020000597A1 (enExample)
CO (1) CO2020004244A2 (enExample)
EA (1) EA202090705A1 (enExample)
EC (1) ECSP20055797A (enExample)
IL (1) IL273174B2 (enExample)
MX (1) MX421623B (enExample)
MY (1) MY204825A (enExample)
PE (1) PE20201166A1 (enExample)
PH (1) PH12020500489A1 (enExample)
SG (1) SG11202002088TA (enExample)
UA (1) UA128690C2 (enExample)
WO (1) WO2019051474A1 (enExample)
ZA (1) ZA202001568B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3005966T3 (en) * 2020-10-19 2025-03-17 Oak Hill Bio Ltd Compositions suitable for use in neonates
IL316413A (en) * 2022-05-04 2024-12-01 Oak Hill Bio Ltd Combination therapy for preterm infants
WO2023242440A1 (en) * 2022-06-17 2023-12-21 Oak Hill Bio Limited Treament of lungs in infants

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008130315A1 (en) * 2007-04-18 2008-10-30 Premacure Ab Method and product for treatment and/or prevention of complications of prematurity

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL71991A (en) 1983-06-06 1994-05-30 Genentech Inc Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes
AU627423B2 (en) 1987-04-06 1992-08-27 Celtrix Pharmaceuticals, Inc. Human somatomedin carrier protein subunits and process for producing them
DK131988A (da) 1988-03-11 1989-09-12 Erasmus University Igf-bindingsprotein, dna-struktur, der koder for igf-bindingsproteinet og vektor indeholdende denne dna-struktur
US5258287A (en) 1988-03-22 1993-11-02 Genentech, Inc. DNA encoding and methods of production of insulin-like growth factor binding protein BP53
DE3854842T2 (de) 1988-04-12 1996-06-13 Amgen Boulder Inc Verfahren zur steigerung und zur hemmung der wirkung eines insulinähnlichen wachstumfaktors
GB8826451D0 (en) 1988-11-11 1988-12-14 Sandoz Ltd Improvements in/relating to organic compounds
IL92816A0 (en) 1988-12-22 1990-09-17 Biogrowth Inc Recombinant dna molecules,hosts,processes and human somatomedin carrier protein-like polypeptides
AU4238493A (en) 1992-05-08 1993-12-13 Thomas Jefferson University IGF-1 analogs
US5563046A (en) 1993-08-02 1996-10-08 Celtrix Pharmaceuticals, Inc. Fusion polypeptides and proteins
US5789547A (en) 1995-06-07 1998-08-04 Celtrix Pharmaceuticals, Inc. Method of producing insulin-like growth factor-I (IGF-I) and insulin-like growth factor binding protein-3 (IGFBP-3) with correct folding and disulfide bonding
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
AU2002239560B2 (en) * 2000-11-28 2006-03-02 Premacure Ab Determination of risk and treatment of complications of prematurity

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008130315A1 (en) * 2007-04-18 2008-10-30 Premacure Ab Method and product for treatment and/or prevention of complications of prematurity

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Chung, JK, et al. "Development and verification of a pharmacokinetic model to optimize physiologic replacement of rhIGF-1/rhIGFBP-3 in preterm infants", Pediatric Research, 2017, vol. 81, no. 3, pages 504-510 *
Hellström, A, et al., "IGF-I in the clinics: Use in retinopathy of prematurity", Growth Horm IGF Res., 2016, vol. 30, pages 75-80 *
Ley, D, et al., "Longitudinal infusion of a complex of insulin-like growth factor-I and IGF-binding protein-3 in five preterm infants: pharmacokinetics and short-term safety.", Pediatric Research, 2013, vol. 73, no. 1, pages 68-74 *

Also Published As

Publication number Publication date
WO2019051474A1 (en) 2019-03-14
EP4663184A3 (en) 2026-03-18
EA202090705A1 (ru) 2020-06-11
IL273174A (en) 2020-04-30
PH12020500489A1 (en) 2021-02-22
EP4663184A2 (en) 2025-12-17
US20220088132A1 (en) 2022-03-24
MY204825A (en) 2024-09-18
UA128690C2 (uk) 2024-10-02
ZA202001568B (en) 2023-09-27
US20190151411A1 (en) 2019-05-23
CA3075482A1 (en) 2019-03-14
KR20200097679A (ko) 2020-08-19
MX2020002744A (es) 2020-10-01
EP3681602B1 (en) 2026-04-15
AU2018328827A1 (en) 2020-04-02
SG11202002088TA (en) 2020-04-29
BR112020004760A2 (pt) 2020-09-15
CN111432881A (zh) 2020-07-17
CO2020004244A2 (es) 2020-05-29
JP2025114869A (ja) 2025-08-05
AU2024227601A1 (en) 2024-11-14
IL273174B2 (en) 2024-12-01
IL273174B1 (en) 2024-08-01
AU2024227601B2 (en) 2026-04-23
MX421623B (es) 2025-03-14
JP2023145646A (ja) 2023-10-11
PE20201166A1 (es) 2020-10-28
EP3681602A1 (en) 2020-07-22
US20240415927A1 (en) 2024-12-19
JP7819893B2 (ja) 2026-02-25
CL2020000597A1 (es) 2020-12-04
JP2020533344A (ja) 2020-11-19
ECSP20055797A (es) 2020-10-30

Similar Documents

Publication Publication Date Title
AU2024227601B2 (en) Methods and compositions for treating chronic lung diseases
TWI912393B (zh) 適用於新生兒的組成物
US9463222B2 (en) Methods for treatment of complications of prematurity comprising administration of IGF-I and IGFBP-3
AU2002239560A1 (en) Determination of risk and treatment of complications of prematurity
HK40033881A (en) Methods and compositions for treating chronic lung diseases
EA044079B1 (ru) Способы и композиции, предназначенные для лечения хронических заболеваний легких
EA049095B1 (ru) Композиции, подходящие для применения у новорожденных
HK40099225B (en) Compositions suitable for use in neonates
HK40099225A (en) Compositions suitable for use in neonates

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Free format text: FORMER APPLICANT(S): SHIRE HUMAN GENETIC THERAPIES, INC.

PC1 Assignment before grant (sect. 113)

Owner name: OAK HILL BIO LIMITED

Free format text: FORMER APPLICANT(S): TAKEDA PHARMACEUTICAL COMPANY LIMITED

FGA Letters patent sealed or granted (standard patent)